FOL 100
Alternative Names: FOL-100Latest Information Update: 24 Nov 2022
Price :
$50 *
At a glance
- Originator Follicle Pharma
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alopecia
Most Recent Events
- 10 Nov 2022 Follicle Pharma has a patent protection for its targeted delivery system platform before November 2022 (Follicle Pharma website, November 2022)
- 20 Oct 2022 Phase-I clinical trials in Alopecia in Israel (Topical) (NCT05611593)